doi:10.16138/j.1673-6087.2022.01.002

Abstract

CLC Number:

R575

Figures/Tables 1

References 52

[1]	Chawla A, Saez E, Evans RM. “Don’t know much bile-ology”[J]. Cell, 2000, 103(1): 1-4. pmid: 11051540
[2]	Russell DW. The enzymes, regulation, and genetics of bile acid synthesis[J]. Annu Rev Biochem, 2003, 72: 137-174. pmid: 12543708
[3]	Trauner M, Meier PJ, Boyer JL. Molecular pathogenesis of cholestasis[J]. N Engl J Med, 1998, 339(17): 1217-1227. doi: 10.1056/NEJM199810223391707 URL
[4]	Ghonem NS, Assis DN, Boyer JL. Fibrates and cholestasis[J]. Hepatology, 2015, 62(2): 635-643. doi: 10.1002/hep.27744 URL
[5]	Cai SY, Boyer JL. Bile infarcts: new insights into the pathogenesis of obstructive cholestasis[J]. Hepatology, 2019, 69(2): 473-475. doi: 10.1002/hep.30291 URL
[6]	Chai J, He Y, Cai SY, et al. Elevated hepatic multidrug resistance-associated protein 3/ATP-binding cassette subfamily C 3 expression in human obstructive cholestasis is mediated through tumor necrosis factor alpha and c-Jun NH2-terminal kinase/stress-activated protein kinase-signaling pathway[J]. Hepatology, 2012, 55(5): 1485-1494. doi: 10.1002/hep.24801 pmid: 22105759
[7]	Chai J, Cai SY, Liu X, et al. Canalicular membrane MRP2/ABCC2 internalization is determined by Ezrin Thr567 phosphorylation in human obstructive cholestasis[J]. J Hepatol, 2015, 63(6): 1440-1448. doi: 10.1016/j.jhep.2015.07.016 pmid: 26212029
[8]	Chai J, Luo D, Wu X, et al. Changes of organic anion transporter MRP4 and related nuclear receptors in human obstructive cholestasis[J]. J Gastrointest Sur, 2011, 15(6): 996-1004.
[9]	Pan Q, Zhang X, Zhang L, et al. Solute carrier organic anion transporter family member 3A1 is a bile acid efflux transporter in cholestasis[J]. Gastroenterology, 2018, 155(5): 1578-1592. doi: 10.1053/j.gastro.2018.07.031 URL
[10]	Corpechot C, Chazouillères O, Rousseau A, et al. A placebo-controlled trial of bezafibrate in primary biliary cholangitis[J]. N Engl J Med, 2018, 378(23): 2171-2181. doi: 10.1056/NEJMoa1714519 URL
[11]	Schwarz M, Russell DW, Dietschy JM, et al. Alternate pathways of bile acid synthesis in the cholesterol 7α-hydroxylase knockout mouse are not upregulated by either cholesterol or cholestyramine feeding[J]. J Lipid Res, 2001, 42(10): 1594-1603. pmid: 11590215
[12]	Kullak-Ublick GA, Stieger B, Meier PJ. Enterohepatic bile salt transporters in normal physiology and liver disease[J]. Gastroenterology, 2004, 126(1): 322-342. doi: 10.1053/j.gastro.2003.06.005 pmid: 14699511
[13]	Trauner M, Boyer JL. Bile salt transporters: molecular characterization, function, and regulation[J]. Physiol Rev, 2003, 83(2): 633-671. doi: 10.1152/physrev.00027.2002 URL
[14]	Lefebvre P, Cariou B, Lien F, et al. Role of bile acids and bile acid receptors in metabolic regulation[J]. Physiol Rev, 2009, 89(1): 147-191. doi: 10.1152/physrev.00010.2008 URL
[15]	Slijepcevic D, Kaufman C, Wichers CG, et al. Impaired uptake of conjugated bile acids and hepatitis B virus pres1-binding in Na⁺-taurocholate cotransporting polypeptide knockout mice[J]. Hepatology, 2015, 62(1): 207-219. doi: 10.1002/hep.27694 pmid: 25641256
[16]	Halilbasic E, Claudel T, Trauner M. Bile acid transporters and regulatory nuclear receptors in the liver and beyond[J]. J Hepatol, 2013, 58(1): 155-168. doi: 10.1016/j.jhep.2012.08.002 pmid: 22885388
[17]	Dawson PA, Lan T, Rao A. Bile acid transporters[J]. J Lipid Res, 2009, 50(12): 2340-2357. doi: 10.1194/jlr.R900012-JLR200 pmid: 19498215
[18]	Slijepcevic D, Roscam Abbing RLP, Fuchs CD, et al. Na⁺-taurocholate cotransporting polypeptide inhibition has hepatoprotective effects in cholestasis in mice[J]. Hepatology, 2018, 68(3): 1057-1069. doi: 10.1002/hep.29888 pmid: 29572910
[19]	Vaz FM, Paulusma CC, Huidekoper H, et al. Sodium taurocholate cotransporting polypeptide (SLC10A1) deficiency: conjugated hypercholanemia without a clear clinical phenotype[J]. Hepatology, 2015, 61(1): 260-267. doi: 10.1002/hep.27240 URL
[20]	Liu R, Chen C, Xia X, et al. Homozygous p.Ser267Phe in SLC10A1 is associated with a new type of hypercholanemia and implications for personalized medicine[J]. Sci Rep, 2017, 7(1): 9214. doi: 10.1038/s41598-017-07012-2 URL
[21]	Pan Q, Luo G, Qu J, et al. A homozygous R148W mutation in semaphorin 7A causes progressive familial intrahepatic cholestasis[J]. EMBO Mol Med, 2021, 13(11): e14563.
[22]	Donkers JM, Kooijman S, Slijepcevic D, et al. NTCP deficiency in mice protects against obesity and hepatosteatosis[J]. JCI Insight, 2019, 5(14): e127197.
[23]	Nigam SK, Bush KT, Martovetsky G, et al. The organic anion transporter (OAT) family: a systems biology perspective[J]. Physiol Rev, 2015, 95(1): 83-123. doi: 10.1152/physrev.00025.2013 URL
[21]	Halilbasic E, Claudel T, Trauner M. Bile acid transporters and regulatory nuclear receptors in the liver and beyond[J]. J Hepatol, 2013, 58(1): 155-168. doi: 10.1016/j.jhep.2012.08.002 pmid: 22885388
[24]	Csanaky IL, Lu H, Zhang Y, et al. Organic anion-transporting polypeptide 1b2 (Oatp1b2) is important for the hepatic uptake of unconjugated bile acids: studies in Oatp1b2-null mice[J]. Hepatology, 2011, 53(1): 272-281. doi: 10.1002/hep.23984 pmid: 20949553
[25]	van de Steeg E, Stránecky V, Hartmannová H, et al. Complete OATP1B1 and OATP1B3 deficiency causes human Rotor syndrome by interrupting conjugated bilirubin reuptake into the liver[J]. J Clin Invest, 2012, 122(2): 519-528. doi: 10.1172/JCI59526 URL
[26]	Ballatori N, Christian WV, Lee JY, et al. OSTα-OSTβ: a major basolateral bile acid and steroid transporter in human intestinal, renal, and biliary epithelia[J]. Hepatology, 2005, 42(6): 1270-1279. doi: 10.1002/hep.20961 URL
[27]	Soroka CJ, Mennone A, Hagey LR, et al. Mouse organic solute transporter alpha deficiency enhances renal excretion of bile acids and attenuates cholestasis[J]. Hepatology, 2010, 51(1): 181-190. doi: 10.1002/hep.23265 pmid: 19902485
[28]	Sultan M, Rao A, Elpeleg O, et al. Organic solute transporter-β (SLC51B) deficiency in two brothers with congenital diarrhea and features of cholestasis[J]. Hepatology, 2018, 68(2): 590-598. doi: 10.1002/hep.29516 pmid: 28898457
[29]	Gao E, Cheema H, Waheed N, et al. Organic solute transporter alpha deficiency: a disorder with cholestasis, liver fibrosis, and congenital diarrhea[J]. Hepatology, 2020, 71(5): 1879-1882. doi: 10.1002/hep.31087 URL
[30]	Boyer JL, Soroka CJ. Bile formation and secretion: an update[J]. J Hepatol, 2021, 75(1): 190-201. doi: 10.1016/j.jhep.2021.02.011 URL
[31]	Xu J, Kausalya PJ, Van Hul N, et al. Protective functions of ZO-2/Tjp2 expressed in hepatocytes and cholangiocytes against liver injury and cholestasis[J]. Gastroenterology, 2021, 160(6): 2103-2118. doi: 10.1053/j.gastro.2021.01.027 URL
[32]	Kubitz R, Dröge C, Kluge S, et al. Autoimmune BSEP disease: disease recurrence after liver transplantation for progressive familial intrahepatic cholestasis[J]. Clin Rev Allergy Immunol, 2015, 48(2-3): 273-284. doi: 10.1007/s12016-014-8457-4 URL
[33]	Cao W, Kayama H, Chen ML, et al. The xenobiotic transporter Mdr1 enforces T cell homeostasis in the presence of intestinal bile acids[J]. Immunity, 2017, 47(6): 1182-1196. doi: 10.1016/j.immuni.2017.11.012 URL
[34]	Kipp H, Arias IM. Trafficking of canalicular ABC transporters in hepatocytes[J]. Annu Rev Physiol, 2002, 64: 595-608. doi: 10.1146/annurev.physiol.64.081501.155793 URL
[35]	Lang C, Meier Y, Stieger B, et al. Mutations and polymorphisms in the bile salt export pump and the multidrug resistance protein 3 associated with drug-induced liver injury[J]. Pharmacogenet Genomics, 2007, 17(1): 47-60. doi: 10.1097/01.fpc.0000230418.28091.76 URL
[36]	Gautherot J, Delautier D, Maubert MA, et al. Phosphorylation of ABCB4 impacts its function: insights from disease-causing mutations[J]. Hepatology, 2014, 60(2): 610-621. doi: 10.1002/hep.27170 pmid: 24723470
[37]	Stieger B. Role of the bile salt export pump, BSEP, in acquired forms of cholestasis[J]. Drug Metab Rev, 2010, 42(3): 437-445. doi: 10.3109/03602530903492004 pmid: 20028269
[38]	Nies AT, Keppler D. The apical conjugate efflux pump ABCC2 (MRP2)[J]. Pflugers Arch, 2007, 453(5): 643-659. doi: 10.1007/s00424-006-0109-y URL
[39]	Beer AJ, Hertz D, Seemann E, et al. Reduced Mrp2 surface availability as PI3Kγ-mediated hepatocytic dysfunction reflecting a hallmark of cholestasis in sepsis[J]. Sci Rep, 2020, 10(1): 13110. doi: 10.1038/s41598-020-69901-3 URL
[40]	Bohan A, Chen WS, Denson LA, et al. Tumor necrosis factor alpha-dependent up-regulation of LRH-1 and MRP3(ABCC3) reduces liver injury in obstructive cholestasis[J]. J Biol Chem, 2003, 278(38): 36688-36698. doi: 10.1074/jbc.M304011200 pmid: 12837754
[41]	Chen W, Cai SY, Xu S, et al. Nuclear receptors RXRα: RARα are repressors for human MRP3 expression[J]. Am J Physiol Gastrointest Liver Physiol, 2007, 292(5): G1221-G1227.
[42]	Zhang X, Wang T, Yang Y, et al. Tanshinone ⅡA attenuates acetaminophen-induced hepatotoxicity through HOTAIR-Nrf2-MRP2/4 signaling pathway[J]. Biomed Pharmacother, 2020, 130: 110547. doi: 10.1016/j.biopha.2020.110547 URL
[43]	Vollrath V, Wielandt AM, Iruretagoyena M, et al. Role of Nrf2 in the regulation of the Mrp2(ABCC2) gene[J]. Biochem J, 2006, 395(3): 599-609. doi: 10.1042/BJ20051518 pmid: 16426233
[44]	Schuetz EG, Strom S, Yasuda K, et al. Disrupted bile acid homeostasis reveals an unexpected interaction among nuclear hormone receptors, transporters, and cytochrome P450[J]. J Biol Chem, 2001, 276(42): 39411-39418. doi: 10.1074/jbc.M106340200 pmid: 11509573
[45]	Mennone A, Soroka CJ, Cai SY, et al. MRP4^-/- mice have an impaired cytoprotective response in obstructive cholestasis[J]. Hepatology, 2006, 43(5): 1013-1021. pmid: 16628672
[46]	Keppler D. The roles of MRP2, MRP3, OATP1B1, and OATP1B3 in conjugated hyperbilirubinemia[J]. Drug Metab Dispos, 2014, 42(4): 561-565. doi: 10.1124/dmd.113.055772 URL
[47]	Fang C, Filipp FV, Smith JW. Unusual binding of ursodeoxycholic acid to ileal bile acid binding protein: role in activation of FXRα[J]. J Lipid Res, 2012, 53(4): 664-673. doi: 10.1194/jlr.M021733 URL
[48]	Harris MJ, Kagawa T, Dawson PA, et al. Taurocholate transport by hepatic and intestinal bile acid transporters is independent of FIC1 overexpression in Madin-Darby canine kidney cells[J]. J Gastroenterol Hepatol, 2004, 19(7): 819-825. doi: 10.1111/j.1440-1746.2004.03347.x URL
[49]	Richter D, Harsch S, Strohmeyer A, et al. MALDI-TOF mass spectrometry screening of cholelithiasis risk markers in the gene of HNF1α[J]. J Proteomics, 2012, 75(12): 3386-3399. doi: 10.1016/j.jprot.2012.04.036 URL
[50]	Chen F, Ma L, Sartor RB, et al. Inflammatory-mediated repression of the rat ileal sodium-dependent bile acid transporter by c-fos nuclear translocation[J]. Gastroenterology, 2002, 123(6): 2005-2016. doi: 10.1053/gast.2002.37055 URL
[51]	Yang N, Dong YQ, Jia GX, et al. ASBT(SLC10A2): a promising target for treatment of diseases and drug discovery[J]. Biomed Pharmacother, 2020, 132: 110835. doi: 10.1016/j.biopha.2020.110835 pmid: 33035828
[52]	Out C, Patankar JV, Doktorova M, et al. Gut microbiota inhibit Asbt-dependent intestinal bile acid reabsorption via Gata4[J]. J Hepatol, 2015, 63(3): 697-704. doi: 10.1016/j.jhep.2015.04.030 URL

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 1

References 52

Related Articles 10

Recommended Articles

Metrics

Comments

[1]	XU Doudou, CHEN Ying, LÜ Ankang, WU Beiwen. A retrospective cohort study on the correlation between triglyceride-glucose index and new-onset fatty liver disease [J]. Journal of Internal Medicine Concepts & Practice, 2022, 17(04): 301-306.
[2]	NING Ling, LIU Zhenjun, LI Wei, LIU Wen, LI Wei, ZHANG Zhenhua, FANG Weidong, GAO Youfang, ZHENG Xiaowei, LI Lei. Pathological and etiological analysis of cholestatic liver disease in Anhui [J]. Journal of Internal Medicine Concepts & Practice, 2022, 17(01): 53-57.
[3]	. [J]. Journal of Internal Medicine Concepts & Practice, 2022, 17(01): 84-87.
[4]	. [J]. Journal of Internal Medicine Concepts & Practice, 2022, 17(01): 1-3.
[5]	. [J]. Journal of Internal Medicine Concepts & Practice, 2022, 17(01): 11-14.
[6]	. [J]. Journal of Internal Medicine Concepts & Practice, 2022, 17(01): 15-23.
[7]	. [J]. Journal of Internal Medicine Concepts & Practice, 2022, 17(01): 24-28.
[8]	. [J]. Journal of Internal Medicine Concepts & Practice, 2022, 17(01): 29-37.
[9]	. [J]. Journal of Internal Medicine Concepts & Practice, 2022, 17(01): 38-42.
[10]	. [J]. Journal of Internal Medicine Concepts & Practice, 2022, 17(01): 43-47.